MoralesA.Androgen replacement therapy and prostate safety. Eur Urol, 2002; 37:1–6.
2.
UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction: Progress Newsletter Issue 67 – 2005. Sexual health—a new focus for WHO, http://www.who.int/reproductive-health/hrp/progress/67.pdf.
WernerA.A.The male climacteric. Report of two hundred and seventy-three cases. JAMA, 1946; 132:188–194.
5.
ThompsonW.O.Uses and abuses of the male sex hormone. JAMA, 1946; 132:185–188.
6.
KaufmanJ.M.Hypothalamic-pituitary-gonadal function in aging men. Aging Male, 1999; 2:157.
7.
NishiyamaT., IshizakiF., AnrakuT., ShimuraH., TakahashiK.The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab, 2005; 90:657–660.
8.
United Nations Department for Economical and Social Information and Policy Analysis. Population Division. World Population Prospects: The 1994 Revision. United Nations, New York Doc; 1995. p. 145.
9.
United Nations Secretariat, Department of Economic and Social Affairs, Populations Division. The 1998 Revision. ESA/P/WP.150. New York United Nations, 1998.
AraujoA.B., O’DonellA.B., BrambillaD.J., SimpsonW.B., LongcopeC., MatsumotoA.M., et al.Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab, 2004; 89:5920–5926.
12.
KaufmanJ.M., VermeulenA.Declining gonadal function in elderly men. Ballieres Clin Endocrinol Metab, 1997; 11:289–309.
HarkonenK., HuhtaniemiI., MakinenJ., HublerD., IrjalaK., KoskenvuoM., et al.The polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in andropausal men. Int J Androl, 2003; 26:187–194.
15.
OhJ.Y., Barrett-ConnorE., WedickN.M., WingardD.L.Endogenous sex hormones and development of type 2 diabetes in older men and women: Rancho-Bernardo study. Diabetes Care, 2002; 25:55–60.
16.
MeigsJ.B., WilsonP.W.F., NathanD.M., A’AgostineR.B., WilliamsK., HaffnerS.M.Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framinham Offspring Studies. Diabetes, 2003; 52:2160–2167.
17.
EnglishK.M., MandourP., SteedsR., DiverM.J., JonesT.H., ChannerK.S.Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J, 1999; 21:890–894.
18.
MalkinC.J., PughP.J., JonesT.H., ChannerK.S.Testosterone for secondary prevention in men with ischaemic heart disease. QJM, 2003; 96:521–529.
19.
BlackA.M., DayA.G.Morales A.: The reliability of clinical and biochemical assessment in symptomatic late onset hypogonadism: can a case be made for a 3 month therapeutic trial?. BJU Int, 2004; 94:1066–1070.
20.
LiuP.Y., SwerdloffR.S., VeldhuisJ.D.Clinical review 171: The rationale, efficacy and safety of androgen therapy in older men: future research and current practice recommendations. J Clin Endocrinol Metab, 2004 Oct;89(10):4789–4796.
21.
ConwayA.J., HandelsmanD.J., LordingD.W., StuckeyB., ZajacJ.D.Use, misuse and abuse of androgens. The Endocrine Society of Australia consensus guidelines for androgen prescribing. Med J Aust, 2000 Mar 6;172(5):220–224.
22.
Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 2002; 288:321–327.
23.
BhasinS., SinghA.B., Phong MacR., CarterB., LeeM.I., CunninghamG.R.Managing the risks of prostate disease during testosterone replacement therapy of older men: Recommendations for a standardized monitoring plan. J Androl, 2003; 24:299–306.
